... occurrence of acromegaly aggravates skull deformity, leading to eye, ear, and posterior cranial fossa compromise. Case Presentation: A 30-year-old man diagnosed with MAS at the age of 3 developed almost all known complications of the syndrome. The craniofacial component of his polyostotic FD increased over...

.... Somatotropinoma Acromegaly Gigantism Pituitary adenoma AIP Pegvisomant Somatostatin analogues Paediatric somatotropinomas are rare tumours and frequently occur in the context of known genetic tumour syndromes. Recent recognition of AIP mutations leading to aggressive paediatric...

...S.J. Neggers; A.J. van der Lely Background: Acromegaly is a growth disorder, but mostly it is a metabolic disease related to excessive production of growth hormone (GH). It is characterized by progressive somatic disfigurement in combination with sometimes severe systemic manifestations. Long...

... with acromegaly. Conclusions: By collecting data on the treatment of relatively rare conditions in routine clinical practice, pharmacoepidemiological surveys such as KIMS and ACROSTUDY provide valuable information on the safety and effectiveness of treatment with GH replacement and pegvisomant in the real world...

... FIPA have higher rates of extension and invasion compared with those in sporadic cases. In somatotropinoma patients from FIPA families, half occur as homogeneous acromegaly families, and 50% in combination with other tumour types (heterogeneous families). Non-secreting pituitary tumours occur...

...% of familial isolated pituitary adenomas (FIPA), in about 50% of cases of familial acromegaly and in a small proportion of acromegalic patients with sporadic presentation. This review describes the genetic and clinical features of published patients with AIP, with either familial or sporadic pituitary tumors...

...Thierry Brue Background: ACROSTUDY is an international noninterventional surveillance study open to all patients with acromegaly treated with the growth hormone antagonist pegvisomant. This web-based registry contains data reflecting actual clinical care of patients, and it is being used to monitor...

... mutation Acromegaly Pituitary adenomas Subcellular localisation HORMONE RESEARCH Abstract Winners Horm Res 2009;71(suppl 1):149 150 DOI: 10.1159/000178061 Published online: January 21, 2009 AIP, a Protein Mutated in Familial Acromegaly, Plays a Role in the Regulation of Cell Proliferation and Shows...

... with pituitary adenomas, not just those with acromegaly. FIPA is a useful clinical framework to study the features of pituitary adenomas that occur in a familial setting since it encompasses all tumor phenotypes and heterogeneous/homogeneous expression among affected family members. Table 1 Familial...

... to improve during octreotide and GH replacement treatment in acromegaly and GHD, respectively. The evidence that GH can increase cardiac mass suggests its use in the treatment of idiopathic dilated cardiomyopathy. In a recent study on such patients, the administration of recombinant GH (rGH) was demonstrated...

... from any ideas, methods, instructions or products referred to in the content or advertisements. Growth hormone History Organotherapy Hypophysectomy Acromegaly Horm one R e se a rch Session 4 Special Lecture Horm Res 1996;46:236-247 Robert Tattersau University Hospital. Nottingham. UK...

...Andrea Giustina; Anna Rosa Bussi; Mauro Doga; William B. Wehrenberg Our recent data show that acute and sustained hypercortisolism decreases circulating growth hormone (GH) levels in acromegaly with respect to saline infusion. It has been hypothesized that in acromegalic patients, as well...

...-function relationship of the human GH molecule and of the interplay of the hormone with its receptor make it conceivable that recombinant analogues of human GH will be designed to inhibit the effects of GH excess in acromegaly. Furthermore, analogues of human GH could be designed to exhibit a modified...

...Carles M. Villabona; Joan Soler; Nuria Virgili; José M. Gómez; Eduard Montaña; Miguel A. Navarro The aim of the study was to analyze 14 consecutive patients with active acromegaly who had not undergone any therapy, the dose response of growth hormone (GH) to thyrotropin-releasing hormone (TRH...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Growth hormone Insulin-like growth factor 1 Thyrotropin-releasing hormone test Luteinizing hormone-releasing hormone test Somatostatin Acromegaly Original Paper Horm Res 1992:37...

...Tamar Amit; Sophia Ish-Shalom; Benjamin Glaser; Moussa B.H. Youdim; Zeev Hochberg The present study was undertaken to investigate the possible regulatory effect of chronic exposure to human growth hormone (hGH), in patients with acromegaly, on growth-hormone-binding protein (GH-BP). Nineteen...

...Andrea Giustina; Anna Rosa Bussi; Massimo Licini; Giuseppe Pizzocolo; Maurizio Schettino; William B. Wehrenberg Aim of our study was to investigate the acute effects of intravenous infusion of hydrocortisone on circulating growth hormone (GH) levels in acromegaly. We studied 5 adult patients...

... cyclase cAMP Acromegaly GH-secreting pituitary adenomas Horm Res 1992;38:90-93 Anna Spacla3 Lucia Vallarb a Institute of Endocrine Sciences. Ospedale Maggiore IRCCS and b Department of Pharmacology. CNR Center of Cytopharmacology, Scientific Institute San Raffaele, University of Milan, Italy Key...

...Jérôme Bertherat; Philippe Chanson; Didier Dewailly; Alain Enjalbert; Philippe Jaquet; Claude Kordon; Françoise Peillon; José Timsit; Jacques Epelbaum The development of a long-acting somatostatin (SRIH) analog (octreotide, Sandoz) has been a major breakthrough in the treatment of acromegaly...

... in hypophysectomized animals a lower than normal incidence of carcinogen-induced neoplasms was reported. In acromegaly, in which there is a pathologically sustained high GH level, there is a significantly increased incidence of cancer in general and specifically of colonic neoplasia. To determine whether the use of GH...